ATE164518T1 - Verwendung von fettsäuren zur behandlung von abnormalen verkalkung des gewebes - Google Patents

Verwendung von fettsäuren zur behandlung von abnormalen verkalkung des gewebes

Info

Publication number
ATE164518T1
ATE164518T1 AT93306445T AT93306445T ATE164518T1 AT E164518 T1 ATE164518 T1 AT E164518T1 AT 93306445 T AT93306445 T AT 93306445T AT 93306445 T AT93306445 T AT 93306445T AT E164518 T1 ATE164518 T1 AT E164518T1
Authority
AT
Austria
Prior art keywords
tissue
fatty acids
treat abnormal
abnormal calcification
prevention
Prior art date
Application number
AT93306445T
Other languages
English (en)
Inventor
David Frederick Horrobin
Meadows Woodbridge
Brenda Elizabeth Reynolds
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of ATE164518T1 publication Critical patent/ATE164518T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT93306445T 1992-08-21 1993-08-16 Verwendung von fettsäuren zur behandlung von abnormalen verkalkung des gewebes ATE164518T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929217781A GB9217781D0 (en) 1992-08-21 1992-08-21 Fatty acid treatment

Publications (1)

Publication Number Publication Date
ATE164518T1 true ATE164518T1 (de) 1998-04-15

Family

ID=10720717

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93306445T ATE164518T1 (de) 1992-08-21 1993-08-16 Verwendung von fettsäuren zur behandlung von abnormalen verkalkung des gewebes

Country Status (17)

Country Link
EP (1) EP0585027B1 (de)
JP (1) JPH06172169A (de)
KR (1) KR940003552A (de)
CN (1) CN1090490A (de)
AT (1) ATE164518T1 (de)
AU (1) AU666748B2 (de)
CA (1) CA2104566A1 (de)
DE (1) DE69317716T2 (de)
DK (1) DK0585027T3 (de)
ES (1) ES2117104T3 (de)
GB (1) GB9217781D0 (de)
GR (1) GR3026708T3 (de)
MY (1) MY131357A (de)
NO (1) NO932984L (de)
NZ (1) NZ248451A (de)
RU (1) RU2122408C1 (de)
ZA (1) ZA936133B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2119000A1 (en) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
EP0734723A4 (de) * 1993-12-29 2001-04-11 Kowa Tekuno Sachi Co Ltd Therapeutisches präparat zur behandlung von hyperparathyroidismus bei dialysepatienten
CA2210856A1 (en) * 1995-01-18 1996-07-25 Taisho Pharmaceutical Co., Ltd. Dermatitis-curing agent
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
JP4607264B2 (ja) * 1998-12-01 2011-01-05 生化学工業株式会社 ヒアルロン酸を有効成分とする異所性石灰化抑制剤
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
EP1392278A4 (de) * 2001-05-14 2005-05-04 Martek Biosciences Corp Herstellung und verwendung einer polaren lipidreichen fraktion mit stearidonsäure und gamma-linolensäure aus pflanzensamen und mikroben
FR2839887A1 (fr) 2002-05-22 2003-11-28 Synergia Nouvelles compositions nutraceutiques et pharmaceutiques et leurs utilisations
JP4575105B2 (ja) * 2004-10-07 2010-11-04 ポリエン・プロジェクト有限会社 骨芽細胞活性抑制剤
CN103202483A (zh) * 2012-01-11 2013-07-17 浙江康恩贝健康产品有限公司 一种补钙营养组合物
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
MX379148B (es) * 2016-06-01 2025-03-10 Soc Des Produits Nestle S A Star Composición para usar en la profilaxis de enfermedades alérgicas.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150248B1 (de) * 1984-02-01 1988-10-19 T P O "Pharmachim" Mittel zur Behandlung und Prophylaxe uratischer und gemischter uratischer Lithiasis
GB8607749D0 (en) * 1986-03-27 1986-04-30 Hetherington A M Compounds & pharmaceutical preparations
DE3781686T2 (de) * 1986-05-02 1993-03-11 Brigham & Womens Hospital Fettsaeure und cyclosporin enthaltende zusammensetzung mit ermaessigter nephrotoxizitaet.
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment

Also Published As

Publication number Publication date
NZ248451A (en) 1997-07-27
NO932984D0 (no) 1993-08-20
MY131357A (en) 2007-08-30
EP0585027B1 (de) 1998-04-01
DK0585027T3 (da) 1998-05-11
DE69317716D1 (de) 1998-05-07
DE69317716T2 (de) 1998-09-17
ZA936133B (en) 1994-03-17
AU666748B2 (en) 1996-02-22
ES2117104T3 (es) 1998-08-01
GB9217781D0 (en) 1992-10-07
AU4474893A (en) 1994-02-24
GR3026708T3 (en) 1998-07-31
KR940003552A (ko) 1994-03-12
EP0585027A1 (de) 1994-03-02
NO932984L (no) 1994-02-22
CA2104566A1 (en) 1994-02-22
JPH06172169A (ja) 1994-06-21
RU2122408C1 (ru) 1998-11-27
CN1090490A (zh) 1994-08-10

Similar Documents

Publication Publication Date Title
ATE159856T1 (de) Verwendung von fettsäuren zur erhöhung der calciumabsorption im darm
ATE43242T1 (de) Pharmazeutische oder diaetetische zusammensetzung mit hoher antithrombotischer und antiarteriosklerotischer wirkung.
ATE264676T1 (de) Verwendung von dha in der behandlung von dyslexie
TW429145B (en) Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA
DE69317716D1 (de) Verwendung von Fettsäuren zur Behandlung von abnormalen Verkalkung des Gewebes
GB8819110D0 (en) Antihypertensive drug & method for production
ATE135208T1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
JPS6422819A (en) Amnesia treating or preventing composition
ATE143261T1 (de) Zusammensetzung zur behandlung entzündlicher darmerkrankungen
DE69832520D1 (de) Verwendung von konjugierten linoleinsäure zur behandlung von type ii diabetes
RU93049092A (ru) Лечение жирными кислотами
DE59303744D1 (de) Mittel zur Behandlung des atopischen Ekzems und anderen entzündlichen Hautkrankheiten
ATE86108T1 (de) Omega-3-fettsaeuren zur behandlung von traumatischen verwundungen.
DE3875637D1 (de) Zusammensetzungen und verfahren zur behandlung von magengeschwueren.
ATE146175T1 (de) Neue kardioprotektive wirkstoffe
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
MY129218A (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee